CATX
HEALTHCAREPerspective Therapeutics Inc.
AI Insight
What's Moving CATX Today?
No stock-specific AI insight has been generated for CATX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.96$6.16
$3.00
Fundamentals
Market Cap$348M
P/E Ratio—
EPS$-1.41
Dividend Yield—
Dividend / Share—
ROE-35.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding114.0M
CATX News
21 articles- Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trialProactive Investors·Jun 3, 2026
- Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a StudyYahoo Finance·Jun 3, 2026
- Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in MelanomaGlobeNewswire Inc.·May 21, 2026
- Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a StudiesYahoo Finance·May 18, 2026
- Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 ResultsYahoo Finance·May 11, 2026
- 4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Perspective Therapeutics to Provide Several Upcoming Corporate UpdatesYahoo Finance·Apr 24, 2026
- Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsightGlobeNewswire Inc.·Apr 20, 2026
- Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual MeetingGlobeNewswire Inc.·Apr 20, 2026
- Perspective Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire Inc.·Apr 2, 2026
- Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026Yahoo Finance·Mar 17, 2026
- Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 ResultsYahoo Finance·Mar 16, 2026
- Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial ProgressYahoo Finance·Feb 18, 2026
- Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial ResultsYahoo Finance·Feb 17, 2026
- Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed?Yahoo Finance·Feb 4, 2026
- Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Feb 2, 2026
- A Look At Perspective Therapeutics (CATX) Valuation After New VMT-α-NET Trial And Pipeline UpdatesYahoo Finance·Feb 2, 2026
- Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 12, 2026
- Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers SymposiumYahoo Finance·Jan 9, 2026
- Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Dec 18, 2025
- Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers SymposiumYahoo Finance·Dec 4, 2025
All 21 articles loaded
Price Data
Open$2.99
Previous Close$3.00
Day High$3.15
Day Low$2.99
52 Week High$6.16
52 Week Low$1.96
52-Week Range
$1.96$6.16
$3.00
Fundamentals
Market Cap$348M
P/E Ratio—
EPS$-1.41
Dividend Yield—
Dividend / Share—
ROE-35.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding114.0M
About Perspective Therapeutics Inc.
Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals. Leveraging state-of-the-art radioisotope technologies, CATX seeks to enhance the precision and effectiveness of cancer therapies, aiming to significantly improve patient survival rates across various malignancies. Backed by a seasoned leadership team and strong strategic alliances, the company is strategically positioned to drive advancements in targeted cancer treatments, addressing significant healthcare challenges in a competitive landscape.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeCommon Stock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—